Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069898 | 0.89 | CTSS (0.47) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL3179611 | 0.86 | CTSS (0.55) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL3168527 | 0.85 | CTSS (0.50) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12356974 | 0.84 | CTSS (0.56) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL14823410 | 0.84 | CTSS (0.56) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL313529 | 0.84 | CTSS (0.56) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL3724991 | 0.83 | CTSS (0.48) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL15205357 | 0.80 | CTSS (0.47) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL10283477 | 0.80 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12369322 | 0.80 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250174-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CTSS 43/4885ADRB3 4433/4885ADRA2B 4379/4885 |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CTSS 43/4885ADRB3 4433/4885ADRA2B 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.